Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab). …
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 Australian Biotech
Latest Video
New Stories
-
PYC to present early polycystic kidney disease trial data at US nephrology conference
October 7, 2026 - - Australian Biotech -
CSL raises US$1.5 billion from US bond investors to refinance debt
October 7, 2026 - - Latest News -
Every serious attempt to reform PBS pricing has run into the same problem
October 7, 2026 - - Latest News -
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 - - Latest News -
The patient who knows what they want is informed and not a danger
October 7, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News